29031
2022
eng
20
14
article
1
--
2022-10-14
--
Identification of disparities in personalized cancer care — a joint approach of the German WERA consortium
(1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the regional impact and the outreach component of MTBs; (2) Methods: we analyzed MTB patient data from four neighboring Bavarian tertiary care oncology centers in Würzburg, Erlangen, Regensburg, and Augsburg, together constituting the WERA Alliance. Absolute patient numbers and regional distribution across the WERA-wide catchment area were weighted with local population densities; (3) Results: the highest MTB patient numbers were found close to the four cancer centers. However, peaks in absolute patient numbers were also detected in more distant and rural areas. Moreover, weighting absolute numbers with local population density allowed for identifying so-called white spots—regions within our catchment that were relatively underrepresented in WERA MTBs; (4) Conclusions: investigating patient data from four neighboring cancer centers, we comprehensively assessed the regional impact of our MTBs. The results confirmed the success of existing collaborative structures with our regional partners. Additionally, our results help identifying potential white spots in providing precision oncology and help establishing a joint WERA-wide outreach strategy.
Cancers
2072-6694
10.3390/cancers14205040
urn:nbn:de:bvb:20-opus-290311
2022-11-04T10:35:19+00:00
sword
swordwue
attachment; filename=deposit.zip
8fd129ff70a63ae0c6bdbde45ab3f48b
Cancers (2022) 14:20, 5040. https://doi.org/10.3390/cancers14205040
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Florian Lüke
Florian Haller
Kirsten Utpatel
Markus Krebs
Norbert Meidenbauer
Alexander Scheiter
Silvia Spoerl
Daniel Heudobler
Daniela Sparrer
Ulrich Kaiser
Felix Keil
Christoph Schubart
Lars Tögel
Sabine Einhell
Wolfgang Dietmaier
Ralf Huss
Sebastian Dintner
Sebastian Sommer
Frank Jordan
Maria-Elisabeth Goebeler
Michaela Metz
Diana Haake
Mithun Scheytt
Elena Gerhard-Hartmann
Katja Maurus
Stephanie Brändlein
Andreas Rosenwald
Arndt Hartmann
Bruno Märkl
Hermann Einsele
Andreas Mackensen
Wolfgang Herr
Volker Kunzmann
Ralf Bargou
Matthias W. Beckmann
Tobias Pukrop
Martin Trepel
Matthias Evert
Rainer Claus
Alexander Kerscher
eng
uncontrolled
precision oncology
eng
uncontrolled
MTB
eng
uncontrolled
patient access
eng
uncontrolled
cancer care
eng
uncontrolled
outreach
eng
uncontrolled
real world data
eng
uncontrolled
outcomes research
Medizin und Gesundheit
open_access
Urologische Klinik und Poliklinik
Pathologisches Institut
Medizinische Klinik und Poliklinik II
Import
Comprehensive Cancer Center Mainfranken
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/29031/cancers-14-05040-v2.pdf
30498
2023
eng
3
13
article
1
--
2023-01-19
--
Expression of the immunohistochemical markers CK5, CD117, and EGFR in molecular subtypes of breast cancer correlated with prognosis
Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort–case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.
Diagnostics
2075-4418
10.3390/diagnostics13030372
urn:nbn:de:bvb:20-opus-304987
2023-03-14T06:03:38+00:00
sword
swordwue
attachment; filename=deposit.zip
12e4140c45c9be021401908edc2482b7
Diagnostics (2023) 13:3, 372. https://doi.org/10.3390/diagnostics13030372
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Carla E. Schulmeyer
Peter A. Fasching
Lothar Häberle
Julia Meyer
Michael Schneider
David Wachter
Matthias Ruebner
Patrik Pöschke
Matthias W. Beckmann
Arndt Hartmann
Ramona Erber
Paul Gass
eng
uncontrolled
early breast cancer
eng
uncontrolled
therapy
eng
uncontrolled
prognosis
eng
uncontrolled
CK5
eng
uncontrolled
CD117
eng
uncontrolled
EGFR
eng
uncontrolled
triple-negative breast cancer
Medizin und Gesundheit
open_access
Pathologisches Institut
Import
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/30498/diagnostics-13-00372-v2.pdf
13567
2012
eng
459
12
article
1
2016-06-30
--
--
Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer
Background: Treatment of patients with stage pT1 urothelial bladder cancer (UBC) continues to be a challenge due to its unpredictable clinical course. Reliable molecular markers that help to determine appropriate individual treatment are still lacking. Loss of aquaporin (AQP) 3 protein expression has previously been shown in muscle-invasive UBC. The aim of the present study was to investigate the prognostic value of AQP3 protein expression with regard to the prognosis of stage pT1 UBC.
Method: AQP 3 protein expression was investigated by immunohistochemistry in specimens of 87 stage T1 UBC patients, who were diagnosed by transurethral resection of the bladder (TURB) and subsequent second resection at a high-volume urological centre between 2002 and 2009. Patients underwent adjuvant instillation therapy with Bacillus Calmette-Guerin (BCG). Loss of AQP3 protein expression was defined as complete absence of the protein within the whole tumour. Expression status was correlated retrospectively with clinicopathological and follow-up data (median: 31 months). Multivariate Cox regression analysis was used to assess the value of AQP3 tumour expression with regard to recurrence-free (RFS), progression-free (PFS) and cancer-specific survival (CSS). RFS, PFS and CSS were calculated by Kaplan-Meier analysis and Log rank test.
Results: 59% of patients were shown to exhibit AQP3-positive tumours, whereas 41% of tumours did not express the marker. Loss of AQP3 protein expression was associated with a statistically significantly worse PFS (20% vs. 72%, p=0.020). This finding was confirmed by multivariate Cox regression analysis (HR 7.58, CI 1.29 - 44.68; p=0.025).
Conclusions: Loss of AQP3 protein expression in pT1 UBC appears to play a key role in disease progression and is associated with worse PFS. Considering its potential prognostic value, assessment of AQP3 protein expression could be used to help stratify the behavior of patients with pT1 UBC.
BMC Cancer
10.1186/1471-2407-12-459
urn:nbn:de:bvb:20-opus-135679
BMC Cancer 2012 12:459. doi:10.1186/1471-2407-12-459
Wolfgang Otto
Peter C. Rubenwolf
Maximilian Burger
Hans-Martin Fritsche
Wolfgang Rößler
Matthias May
Arndt Hartmann
Ferdinand Hofstädter
Wolf F. Wieland
Stefan Denzinger
eng
uncontrolled
urothelial bladder carcinoma
eng
uncontrolled
progression
eng
uncontrolled
transitional cell carcinoma
eng
uncontrolled
bacillus calmette guerin
eng
uncontrolled
water channels
eng
uncontrolled
follow up
eng
uncontrolled
in vitro
eng
uncontrolled
recurrence
eng
uncontrolled
growth
eng
uncontrolled
T1
eng
uncontrolled
tumor
eng
uncontrolled
proliferation
eng
uncontrolled
stage pT1
eng
uncontrolled
aquaporin 3 protein
eng
uncontrolled
immunohistochemistry
Gynäkologie, Geburtsmedizin, Pädiatrie, Geriatrie
open_access
Urologische Klinik und Poliklinik
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/13567/Otto_BMCCancer_2012.pdf
11416
2015
eng
doctoralthesis
1
2015-06-08
--
2015-04-29
Optimization and Design of Network Architectures for Future Internet Routing
Optimierung und Design von Netzwerkarchitekturen für zukünftiges Internet Routing
At the center of the Internet’s protocol stack stands the Internet Protocol (IP) as a common denominator that enables all communication. To make routing efficient, resilient, and scalable, several aspects must be considered. Care must be taken that traffic is well balanced to make efficient use of the existing network resources, both in failure free operation and in failure scenarios.
Finding the optimal routing in a network is an NP-complete problem. Therefore, routing optimization is usually performed using heuristics. This dissertation shows that a routing optimized with one objective function is often not good when looking at other objective functions. It can even be worse than unoptimized routing with respect to that objective function. After looking at failure-free routing and traffic distribution in different failure scenarios, the analysis is extended to include the loop-free alternate (LFA) IP fast reroute mechanism. Different application scenarios of LFAs are examined and a special focus is set on the fact that LFAs usually cannot protect all traffic in a network even against single link failures. Thus, the routing optimization for LFAs is targeted on both link utilization and failure coverage. Finally, the pre-congestion notification mechanism PCN for network admission control and overload protection is analyzed and optimized. Different design options for implementing the protocol are compared, before algorithms are developed for the calculation and optimization of protocol parameters and PCN-based routing.
The second part of the thesis tackles a routing problem that can only be resolved on a global scale. The scalability of the Internet is at risk since a major and intensifying growth of the interdomain routing tables has been observed. Several protocols and architectures are analyzed that can be used to make interdomain routing more scalable. The most promising approach is the locator/identifier (Loc/ID) split architecture which separates routing from host identification. This way, changes in connectivity, mobility of end hosts, or traffic-engineering activities are hidden from the routing in the core of the Internet and the routing tables can be kept much smaller. All of the currently proposed Loc/ID split approaches have their downsides. In particular, the fact that most architectures use the ID for routing outside the Internet’s core is a poor design, which inhibits many of the possible features of a new routing architecture. To better understand the problems and to provide a solution for a scalable routing design that implements a true Loc/ID split, the new GLI-Split protocol is developed in this thesis, which provides separation of global and local routing and uses an ID that is independent from any routing decisions.
Besides GLI-Split, several other new routing architectures implementing Loc/ID split have been proposed for the Internet. Most of them assume that a mapping system is queried for EID-to-RLOC mappings by an intermediate node at the border of an edge network. When the mapping system is queried by an intermediate node, packets are already on their way towards their destination, and therefore, the mapping system must be fast, scalable, secure, resilient, and should be able to relay packets without locators to nodes that can forward them to the correct destination. The dissertation develops a classification for all proposed mapping system architectures and shows their similarities and differences. Finally, the fast two-level mapping system FIRMS is developed. It includes security and resilience features as well as a relay service for initial packets of a flow when intermediate nodes encounter a cache miss for the EID-to-RLOC mapping.
Daten durch das Internet werden heutzutage mit dem paketbasierten Internet Protokoll (IP) übertragen. Dezentralisierte Routingprotokolle innerhalb der einzelnen Netze sorgen für eine zielgerichtete Weiterleitung der einzelnen Pakete. Diese verteilten Protokolle können auch im Fehlerfall weiterarbeiten, benötigen aber mitunter sehr lange bis Daten wieder zuverlässig am Ziel ankommen. Um im Betrieb des Internets eine hohe Leistungsfähigkeit auch bei auftretenden Problemfällen zu gewährleisten, müssen die eingesetzten Protokolle optimal eingestellt werden.
Zielfunktionen zur Optimierung paketbasierter Link-State Intradomain-Routingprotokolle: Ein wichtiger Faktor für die Performanz eines Netzes ist die Auswahl der administrativen Linkkosten, anhand derer die Weiterleitungsentscheidungen im Netz getroffen werden. Mit Hilfe von Modellen für Verkehrsaufkommen und für die darunterliegende Netzarchitektur kann mit geeigneten Optimierungsmethoden das Netz für verschiedene Szenarien bestmöglich eingestellt werden. Von besonderer Wichtigkeit ist hierbei die Auswahl der betrachteten Szenarien und Zielfunktionen für die Optimierung. Eine Routingkonfiguration die optimal für ein bestimmtes Ziel ist, kann beliebig schlecht für ein anderes Ziel sein. Zum Beispiel kann eine Konfiguration, die eine besonders hohe Fehlerabdeckung erreicht, zu einer sehr schlechten Verkehrsverteilung führen. Im Rahmen der Dissertation werden heuristische Optimierungen des Routings für verschiedene Protokolle und Anwendungsszenarien durchgeführt. Darüber hinaus wird eine Pareto-Optimierung implementiert, die gleichzeitig mehrere Ziele optimieren kann. Die Analysen werden zuerst für normales Routing im fehlerfreien Fall und für Fehlerszenarien durchgeführt. Daraufhin werden verschiedenste Anwendungsfälle des IP Fast-Reroute Mechanismus Loop-Free Alternates (LFA) betrachtet. Hier wird insbesondere auf die Problematik eingegangen, dass LFAs in Abhängigkeit vom eingestellten Routing in bestimmten Fehlerfällen nicht angewendet werden können. Beim Optimieren des Routings muss hier zusätzlich zur Lastverteilung auch noch die Maximierung der Fehlerabdeckung berücksichtigt werden. Schließlich folgt eine Untersuchung und Optimierung des Pre-Congestion Notification (PCN) Verfahren zur Netzzugangskontrolle und Überlaststeuerung. Hier werden verschiedene Architekturvarianten des Protokolls miteinander verglichen und Algorithmen zur Berechnung und Optimierung wichtiger Parameter des Protokolls entwickelt.
Das Wachstum der Routingtabellen im Kern des Internets droht zu einem Skalierbarkeitsproblem zu werden. Ein Grund für diese Problematik ist die duale Funktion der IP-Adresse. Sie wird einerseits zur Identifikation eines Geräts benutzt und andererseits zur Weiterleitung der Daten zu diesem Gerät. Neue Mechanismen und Protokolle die eine Trennung zwischen den beiden Funktionalitäten der IP-Adresse ermöglichen sind potentielle Kandidaten für eine bessere Skalierbarkeit des Internetroutings und damit für die Erhaltung der Funktionalität des Internets.
Design eines neuen Namens- und Routingprotokolls für skalierbares Interdomain-Routing: In der Dissertation werden grundlegende Eigenschaften die zu diesem Problem führen erörtert. Daraufhin werden vorhandene Ansätze zur Verbesserung der Skalierbarkeit des Internetroutings analysiert, und es werden Gemeinsamkeiten wie auch Schwachstellen identifiziert. Auf dieser Basis wird dann ein Protokoll entwickelt, das eine strikte Trennung zwischen Identifikationsadressen (IDs) und routebaren Locator-Adressen einhält. Das GLI-Split genannte Protokoll geht dabei über den einfachen Split von vorhandenen Architekturvorschlägen hinaus und führt eine weitere Adresse ein die nur für das lokale Routing innerhalb eines Endkunden-Netzes benutzt wird. Hierdurch wird die ID eines Endgeräts vollständig unabhängig vom Routing. Durch das GLI-Split Protokoll kann das globale Routing wieder skalierbar gemacht werden. Zusätzlich bietet es viele Vorteile für Netze die das Protokoll einführen, was als Anreiz nötig ist um den Einsatz eines neuen Protokolls zu motivieren. Solch ein Identifier/Locator Split Protokoll benötigt ein Mappingsystem um die Identifier der Endgeräte in routebare Locator-Adressen zu übersetzen. Im letzten Teil der Dissertation wird eine mehrstufige Mapping-Architektur namens FIRMS entwickelt. Über ein hierarchisches Verteilungssystem, das die Adressvergabestruktur der fünf Regionalen Internet Registrare (RIRs) und der darunterliegenden Lokalen Internet Registrare (LIRs) abbildet, werden die erforderlichen Zuordnungstabellen so verteilt, dass jederzeit schnell auf die benötigten Informationen zugegriffen werden kann. Hierbei wird auch besonders auf Sicherheitsaspekte geachtet.
1432-8801
urn:nbn:de:bvb:20-opus-114165
10.25972/OPUS-11416
X 126082
Deutsches Urheberrecht mit Print on Demand
Matthias Hartmann
Würzburger Beiträge zur Leistungsbewertung Verteilter Systeme
02/15
deu
swd
Netzwerk
deu
swd
Routing
deu
swd
Optimierung
deu
swd
Netzwerkmanagement
eng
uncontrolled
Optimization
eng
uncontrolled
Future Internet
Datenverarbeitung; Informatik
Routing protocols (NEW)
open_access
Institut für Informatik
Universität Würzburg
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/11416/hartmann_matthias_dissertation.pdf
14873
2015
eng
477-487
4
7
article
1
2017-05-17
--
--
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination andpoor prognosis. We evaluated the novel CXCR4 probe [\(^{68}\)Ga]Pentixafor for invivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [\(^{68}\)Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [\(^{68}\)Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [\(^{18}\)F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34\(^{+}\) flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [\(^{68}\)Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases.
EMBO Molecular Medicine
10.15252/emmm.201404698
urn:nbn:de:bvb:20-opus-148738
EMBO Molecular Medicine 7(4), 477-487 (2015). DOI: 10.15252/emmm.201404698
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Kathrin Philipp-Abbrederis
Ken Herrmann
Stefan Knop
Margret Schottelius
Matthias Eiber
Katharina Lückerath
Elke Pietschmann
Stefan Habringer
Carlos Gerngroß
Katharina Franke
Martina Rudelius
Andreas Schirbel
Constantin Lapa
Kristina Schwamborn
Sabine Steidle
Elena Hartmann
Andreas Rosenwald
Saskia Kropf
Ambros J Beer
Christian Peschel
Hermann Einsele
Andreas K Buck
Markus Schwaiger
Katharina Götze
Hans-Jürgen Wester
Ulrich Keller
eng
uncontrolled
FDG PET/CT
eng
uncontrolled
cells
eng
uncontrolled
CXCR4/SDF-1
eng
uncontrolled
CXCR4
eng
uncontrolled
multiple myeloma
eng
uncontrolled
positron emission tomography
eng
uncontrolled
chemokine receptor
eng
uncontrolled
in vivo imaging
eng
uncontrolled
malignancies
eng
uncontrolled
involvement
eng
uncontrolled
microenvironment
eng
uncontrolled
survival
eng
uncontrolled
cancer
eng
uncontrolled
autologous transplantation
eng
uncontrolled
bone disease
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Pathologisches Institut
Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II)
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/14873/043_Philipp-Abbrederis_EMBO_Molecular_Medicine.pdf
21850
2020
eng
1
55
article
1
--
--
--
Human iPSC‐Derived Blood‐Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?
Translating basic biological knowledge into applications remains a key issue for effectively tackling neurodegenerative, neuroinflammatory, or neuroendocrine disorders. Efficient delivery of therapeutics across the neuroprotective blood‐brain barrier (BBB) still poses a demanding challenge for drug development targeting central nervous system diseases. Validated in vitro models of the BBB could facilitate effective testing of drug candidates targeting the brain early in the drug discovery process during lead generation. We here review the potential of mono‐ or (isogenic) co‐culture BBB models based on brain capillary endothelial cells (BCECs) derived from human‐induced pluripotent stem cells (hiPSCs), and compare them to several available BBB in vitro models from primary human or non‐human cells and to rodent in vivo models, as well as to classical and widely used barrier models [Caco‐2, parallel artificial membrane permeability assay (PAMPA)]. In particular, we are discussing the features and predictivity of these models and how hiPSC‐derived BBB models could impact future discovery and development of novel CNS‐targeting therapeutics.
Current Protocols in Stem Cell Biology
10.1002/cpsc.122
urn:nbn:de:bvb:20-opus-218509
2020-12-07T15:07:23+00:00
sword
swordwue
attachment; filename=deposit.zip
c087f8b78220cee285f9dd0fbe88b535
Current Protocols in Stem Cell Biology 2020, 55(1), e122. DOI: 10.1002/cpsc.122
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Antje Appelt‐Menzel
Sabrina Oerter
Sanjana Mathew
Undine Haferkamp
Carla Hartmann
Matthias Jung
Winfried Neuhaus
Ole Pless
eng
uncontrolled
blood‐brain barrier (BBB)
eng
uncontrolled
CNS disease
eng
uncontrolled
drug permeability screening
eng
uncontrolled
human‐induced pluripotent stem cells (hiPSC)
eng
uncontrolled
preclinical drug discovery
Biowissenschaften; Biologie
open_access
Lehrstuhl für Tissue Engineering und Regenerative Medizin
Import
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/21850/CPSC_CPSC122.pdf
32406
2023
eng
5417-5428
8
149
article
1
--
--
--
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Purpose
Therapeutic options for breast cancer (BC) treatment are constantly evolving. The Human Epidermal Growth Factor 2 (HER2)-low BC entity is a new subgroup, representing about 55% of all BC patients. New antibody–drug conjugates demonstrated promising results for this BC subgroup. Currently, there is limited information about the conversion of HER2 subtypes between primary tumor and recurrent disease.
Methods
This retrospective study included women with BC at the University Medical Centre Wuerzburg from 1998 to 2021. Data were retrieved from patients' records. HER2 evolution from primary diagnosis to the first relapse and the development of secondary metastases was investigated.
Results
In the HR-positive subgroup without HER2 overexpression, HER2-low expression in primary BC was 56.7 vs. 14.6% in the triple-negative subgroup (p < 0.000). In the cohort of the first relapse, HER2-low represented 64.1% of HR-positive vs. 48.2% of the triple-negative cohort (p = 0.03). In patients with secondary metastases, HER2-low was 75.6% vs. 50% in the triple negative subgroup (p = 0.10). The subgroup of HER2-positive breast cancer patients numerically increased in the course of disease; the HER2-negative overall cohort decreased. A loss of HER2 expression from primary BC to the first relapse correlated with a better OS (p = 0.018). No clinicopathological or therapeutic features could be identified as potential risk factors for HER2 conversion.
Conclusion
HER2 expression is rising during the progression of BC disease. In view of upcoming therapeutical options, the re-analysis of newly developed metastasis will become increasingly important.
Journal of Cancer Research and Clinical Oncology
10.1007/s00432-022-04486-0
urn:nbn:de:bvb:20-opus-324068
@articleLob.2023, author = Löb, Sanja and Linsmeier, Eva and Herbert, Saskia-Laureen and Schlaiß, Tanja and Kiesel, Matthias and Wischhusen, Jörg and Salmen, Jessica and Kranke, Peter and Quenzer, Anne and Kurz, Florian and Weiss, Claire and Gerhard-Hartmann, Elena and Wöckel, Achim and Diessner, Joachim, year = 2023, title = Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases, pages = 5417–5428, volume = 149, number = 8, journal = Journal of cancer research and clinical oncology, doi = 10.1007/s00432-022-04486-0
md5:e113f841519478943c6b695435538d43
2023-08-12T09:17:59+00:00
/tmp/php6I4Lsu
bibtex
64d74e47438da6.27035781
Journal of Cancer Research and Clinical Oncology (2023) 149:8, 5417-5428 DOI: 10.1007/s00432-022-04486-0
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Sanja Löb
Eva Linsmeier
Saskia-Laureen Herbert
Tanja Schlaiß
Matthias Kiesel
Jörg Wischhusen
Jessica Salmen
Peter Kranke
Anne Quenzer
Florian Kurz
Claire Weiss
Elena Gerhard-Hartmann
Achim Wöckel
Joachim Diessner
eng
uncontrolled
breast cancer
eng
uncontrolled
HER2 conversion
eng
uncontrolled
HER2-low
eng
uncontrolled
trastuzumab deruxtecan
eng
uncontrolled
HER2 targeted therapy
eng
uncontrolled
trastuzumab
Gynäkologie, Geburtsmedizin, Pädiatrie, Geriatrie
open_access
Frauenklinik und Poliklinik
Pathologisches Institut
Klinik und Poliklinik für Anästhesiologie (ab 2004)
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/32406/s00432-022-04486-0.pdf
31934
2023
eng
11
12
article
1
--
2023-05-28
--
Physical function of RA patients tapering treatment — a post hoc analysis of the randomized controlled RETRO trial
Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline.
Journal of Clinical Medicine
2077-0383
10.3390/jcm12113723
urn:nbn:de:bvb:20-opus-319349
2023-06-07T11:30:26+00:00
sword
swordwue
attachment; filename=deposit.zip
09a4d0bccad10e0d14898537102e0e2f
Journal of Clinical Medicine (2023) 12:11, 3723. https://doi.org/10.3390/jcm12113723
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Marlene Stephan
Koray Tascilar
Melek Yalcin-Mutlu
Melanie Hagen
Judith Haschka
Michaela Reiser
Fabian Hartmann
Arnd Kleyer
Axel J. Hueber
Bernhard Manger
Camille Figueiredo
Jayme Fogagnolo Cobra
Hans-Peter Tony
Stephanie Finzel
Stefan Kleinert
Jörg Wendler
Florian Schuch
Monika Ronneberger
Martin Feuchtenberger
Martin Fleck
Karin Manger
Wolfgang Ochs
Matthias Schmitt-Haendle
Hannes Martin Lorenz
Hubert Nüsslein
Rieke Alten
Joerg Henes
Klaus Krüger
Georg Schett
Jürgen Rech
eng
uncontrolled
HAQ
eng
uncontrolled
Rheumatoid Arthritis
eng
uncontrolled
PROM’s
eng
uncontrolled
DMARD
eng
uncontrolled
DAS28
Medizin und Gesundheit
open_access
Medizinische Klinik und Poliklinik II
Import
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/31934/jcm-12-03723.pdf